Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.41 |
| ▸ | PER2 | O15055 | 8/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232947 | 0.83 | GRM2 (0.47) | CYP2C9NR1I2GRM2HIF1A | |
| SCHEMBL7078510 | 0.80 | CYP2C9 (0.52) | CYP2C9NR1I2PLK1PER2HIF1A | |
| SCHEMBL23411784 | 0.77 | KDM4E (0.44) | — | |
| SCHEMBL5332751 | 0.77 | ALDH1A1 (0.60) | CYP2C9NR1I2HIF1A | |
| SCHEMBL6688684 | 0.77 | CYP2C9 (0.78) | CYP2C9NR1I2PLK1 | |
| SCHEMBL8243641 | 0.76 | HIF1A (0.67) | CYP2C9NR1I2HIF1A | |
| SCHEMBL5335435 | 0.75 | ALDH1A1 (0.57) | CYP2C9NR1I2HIF1A | |
| SCHEMBL5330885 | 0.74 | ALDH1A1 (0.56) | CYP2C9NR1I2HIF1A | |
| SCHEMBL5089690 | 0.72 | CYP2C9 (1.00) | CYP2C9NR1I2PLK1PER2HIF1A | |
| SCHEMBL3579001 | 0.72 | CYP2C9 (0.71) | CYP2C9NR1I2PLK1PER2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032177-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | POLR2E, POLR2H, POLR2A | CYP2C9 2562/4885NR1I2 546/4885PLK1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.